An open-label clinical trial described durable clinical and renal remission in a patient with severe relapsed and refractory lupus nephritis after treatment with allogeneic CD19-targeted CAR-NK cells. The report focuses on sustained response rather than short-term biomarker movement. The update reinforces continued interest in CAR-NK approaches as an off-the-shelf alternative to CAR-T, aiming to reduce manufacturing and safety constraints associated with autologous products. In lupus nephritis, durable organ response has been a key unmet need given heterogeneous disease drivers and limited long-term options. While this is a single patient experience, it provides a tangible clinical datapoint for programs positioning NK platforms for autoimmune indications and supports ongoing development discussions around dosing, persistence, and immune safety.